Newswire (Published: Thursday, April 11, 2019, Received: Thursday, April 11, 2019, 3:35:33 PM CDT)

Word Count: 410

2019 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news reporting out of Heidelberg, Germany, by NewsRx editors, research stated, “Prostate cancers harboring DNA repair gene alterations are particularly sensitive to PARP inhibitor treatment. We report a case of an advanced prostate cancer patient profiled within the NCT-MASTER (Molecularly Aided Stratification for Tumor Eradication Research) precision oncology program using next-generation sequencing.”

Our news journalists obtained a quote from the research from National Center for Tumor Diseases, “Comprehensive genomic and transcriptomic analysis identified a pathogenic germline variant as well as a mutational signature associated with disturbed homologous recombination together with structural genomic rearrangements. A molecular tumor board identified a potential benefit of targeted therapy and recommended PARP inhibition and platinum-based chemotherapy. Single-agent treatment with the PARP inhibitor olaparib as well as subsequent combination with platinum-based chemotherapy resulted in disease stabilization and substantial improvement of clinical symptoms.”

According to the news editors, the research concluded: “Upon progression, we performed whole-exome and RNA sequencing of a liver metastasis, which demonstrated up-regulation of several genes characteristic for the neuroendocrine prostate cancer phenotype as well as a novel translocation resulting in an in-frame, loss-of-function fusion of We suggest that multidimensional genomic characterization of prostate cancer patients undergoing PARP inhibitor therapy will be necessary to capture and understand predictive biomarkers of PARP inhibitor sensitivity and resistance.”

For more information on this research see: Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Molecular Case Studies, 2019;5(2):a003657.

Our news journalists report that additional information may be obtained by contacting P. Horak, Dept. of Translational Medical Oncology, National Center for Tumor Diseases, 69120 Heidelberg, Germany. Additional authors for this research include J. Weischenfeldt, G. von Amsberg, B. Beyer, A. Schutte, S. Uhrig, L. Gieldon, B. Klink, L. Feuerbach, D. Hubschmann, S. Kreutzfeldt, C. Heining, S. Maier, B. Hutter, R. Penzel, M. Schlesner, R. Eils and G. Sauter.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1101/mcs.a003657. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Places

Western Europe
Germany
Europe

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Genetics
                  Functional and Comparative Genomics
                  Genomics